Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03236116 · ClinicalTrials.gov registry record · NA
Almond Consumption and Glycemia
A NA study of Glucose Intolerance and Glucose Metabolism Disorders (Including Diabetes Mellitus), sponsored by Purdue University.
- Completed
- Registry status
- NA
- Development phase
- 75
- Enrollment target
- 3
- Study locations
NCT03236116: Completed NA study of Glucose Intolerance and Glucose Metabolism Disorders (Including Diabetes Mellitus), sponsored by Purdue University.
NCT03236116 is a NA study of Glucose Intolerance and Glucose Metabolism Disorders (Including Diabetes Mellitus) that has completed, run by Purdue University. The registered enrollment target is 75 participants, below the 3,854-participant average among 14 other Glucose Intolerance trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03236116, a NA study of Glucose Intolerance and Glucose Metabolism Disorders (Including Diabetes Mellitus), has completed, sponsored by Purdue University.
- COMPLETED
- Registry status
- NA
- Development phase
- 75 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will examine the effects of almonds consumed by adults with different body fat distributions on indices of carbohydrate and lipid metabolism.
Primary Outcome
HbA1c.
Conditions Studied
Interventions
- OTHER Almonds
- OTHER Control (no nuts)
Study Locations (3)
Indiana
- Indiana University School of Medicine - Indianapolis
- Purdue University - West Lafayette
- Purdue University - West Lafayette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2020-12-31 |
| Phase | NA |
What the finished NCT03236116 record still lists
NCT03236116 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 3,854-participant average among 14 other Glucose Intolerance trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Glucose Intolerance appearing as the primary indexed condition, and to 2 interventions - of which Almonds is the first listed.
NCT03236116 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT03236116 about?
NCT03236116 is a clinical study titled "Almond Consumption and Glycemia". This study will examine the effects of almonds consumed by adults with different body fat distributions on indices of carbohydrate and lipid metabolism.
What is the current status of trial NCT03236116?
This trial is currently completed. It is a NA study. The enrollment target is 75 participants. The study started on 2017-08-01. Estimated completion is 2020-12-31.
What conditions does trial NCT03236116 study?
This clinical trial studies the following conditions: Glucose Intolerance, Glucose Metabolism Disorders (Including Diabetes Mellitus), Lipid Metabolism Disorder, Appetite Disorders.
What interventions are being tested in trial NCT03236116?
The interventions under investigation include: Almonds (OTHER), Control (no nuts) (OTHER).
Who is sponsoring clinical trial NCT03236116?
This trial is sponsored by Purdue University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03236116 being conducted?
This trial has 3 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glucose Intolerance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03236116's enrollment target sits among peer trials
75 6th of 14 higher than 9 of 14 other Glucose Intolerance trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glucose Intolerance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Impact of Overnight Nutrition Support on Sleep and Circadian Rhythm Disruption in the ICU
RECRUITING · NA
-
Time to Move in Pregnancy Hyperglycemia
RECRUITING · NA
-
The Impact of Removal of Exercise on Glycemic Control and Vascular Health in Older Active Adults
RECRUITING · NA
-
Sleep and Metabolism
RECRUITING · NA
-
The Acute T-Rex (Timing of Resistance Exercise) Study
RECRUITING · NA
-
Use of Continuous Glucose Monitoring in Non-Diabetic Population to Compliment Signos Mobile Health Platform
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI